Transmyocardial Laser Revascularization Market to Develop Rapidly by 2025

Transmyocardial laser revascularization has emerged as a better treatment alternative for ischemic heart disease patients who are unable to undergo surgeries such as coronary artery bypass graft surgery or stenting by balloon angioplasty. Introduced in 1990, transmyocardial laser revascularization (TMLR) procedure bores small holes from the ventricle into the myocardium and provides significant relief to angina patients by allowing the direct flow of blood to heart muscles, thereby surpassing the need to transport supporting device such as coronary guidewires through blocked arteries. The growing patient population suffering from weakened blood veins owing to type 2 diabetes, obesity, and other conditions resulting in metabolic disorders has led to increased need for thorough investigation of transmyocardial laser revascularization as an effective substitute for difficult-to-treat patients.

Reduced probability of re-admission, along with improvement in quality of life of the patient are likely to drive the growth of the global Transmyocardial Laser Revascularization Market during the forecast period. Currently, nearly 40% of the overall transmyocardial laser revascularization procedures are performed in the U.S. alone, which reflects the significant growth opportunity for improvement in the adoption rate of the transmyocardial laser revascularization technique in other high growth potential developing countries. However, requirement of skilled personnel having utmost precision, and concerns related to inconsistency of the perfusion improvement data are likely to restrain the growth of the global transmyocardial laser revascularization market during the forecast period. The growth in research and development addressing the issue of consistent myocardial perfusion, along with long term survival without the need of readmission is likely to serve as a major opportunity for the growth of the global transmyocardial laser revascularization market during the forecast period.

Request to View Brochure of Report -

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=39371

The global transmyocardial laser revascularization market can be categorized on the basis of laser modality type, angina stage type, end-user, and region. On the basis of laser modality type, the global transmyocardial laser revascularization market can be bifurcated into holmium:yttrium–aluminum–garnet (Ho:YAG) lasers and Caron Di-oxide (CO2) lasers, which are approved by the FDA. Also, several other experimented wavelength include, but are not limited to xenon–chloride, and neodymium:yttrium–aluminum–garnet (YAG) lasers.

Based on angina stage type, the global transmyocardial laser revascularization market can be classified into angina class I, angina class II, angina class III, and angina class IV. In terms of end-user, the global transmyocardial laser revascularization market can be divided into hospitals, ambulatory surgical centers, & specialty clinics. Among the two FDA approved laser modalities, CO2 laser uses a wavelength of 10,600nm whereas Ho:YAG laser uses 2,120nm wavelength. Studies have shown that CO2 lasers create 3.5 times lesser structural and thermal damage zones to the tissues when compared to Ho:YAG laser, thus resulting in lower volumetric tissue damage.

Request to View ToC of Report -

https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=39371

Geographically, the global transmyocardial laser revascularization market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is likely to account for a leading share of the global transmyocardial laser revascularization market, during the forecast period, in terms of value, owing to significant adoption rate of transmyocardial laser revascularization technique, favorable reimbursement scenario, and rising prevalence of ischemic heart disease led by lifestyle-related diseases in this region. Asia Pacific is projected to offer significant potential for growth of the transmyocardial laser revascularization market during the forecast period, in terms of value, owing to rising prevalence of diabetes and obesity leading to weakened veins, and increasing per capita expenditure on health care in the region.

Key players operating in the global transmyocardial laser revascularization market having FDA approval are NOVADAQ Technologies Inc., and CryoLife, Inc.

View Report -

https://www.transparencymarketresearch.com/transmyocardial-laser-revascularization-market.html

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com

This release was published on openPR.